Samit Hirawat, Bristol Myers Squibb CMO (Bristol Myers)

Bris­tol My­ers wins a megablock­buster bet with TYK2 FDA ap­proval — and there's a big bonus for the la­bel

Bris­tol My­ers Squibb made a megablock­buster bet on deu­cravac­i­tinib, an in-house ex­per­i­men­tal TYK2 drug, in the lead­up to the big Cel­gene buy­out, keep­ing it while auc­tion­ing off Cel­gene’s top-sell­ing Ote­zla to Am­gen for $13.4 bil­lion.

Fri­day evening, that bet paid off in a land­mark win, with Bris­tol My­ers get­ting a green light to sell the first-in-class oral pso­ri­a­sis drug — as So­tyk­tu (get it?) — for $75,000 a year as an­a­lysts project peak sales in the $3 bil­lion-plus range. And there’s a big bonus: The cheer­ing sec­tion of the an­a­lysts on du­ty here breathed a sigh of re­lief that the FDA didn’t slap it with a black box warn­ing for its re­la­tion to the JAK fam­i­ly — where strict safe­ty warn­ings are promi­nent.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.